Clinical Trial Update: Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients

View source ↗

Summary

This ClinicalTrials.gov update notes an ongoing study evaluating the relationship between Fibroblast Growth Factor 23 levels and the risk of cardiac arrhythmias…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Snippet

Sponsor: Antonio Bellasi | Conditions: Hemodialysis | Status: RECRUITING